What is the recommended treatment for β‑thalassemia major?

Treatment of β-Thalassemia Major

For patients with β-thalassemia major who have an HLA-matched sibling donor, proceed with hematopoietic stem cell transplantation (HSCT) as early as possible—ideally before age 14 and before iron-related organ damage develops—as this offers the only curative option with disease-free survival rates of 83-96%. 1

Treatment Algorithm

First-Line Curative Approach: HSCT

When to transplant:

• Perform HSCT as soon as an HLA-identical sibling or well-matched related/unrelated donor is identified 1
• Critical timing: Transplant before age 14 years achieves optimal outcomes (96% disease-free survival vs. 74% in older patients) 1
• Transplant before iron overload causes organ dysfunction—this is the single most important predictor of outcome 1

Expected outcomes with modern techniques:

• Overall survival: 91%
• Disease-free survival: 83% overall, 96% in children under 14 years 1
• Transplant-related mortality: ≤5% in young, low-risk children with matched sibling donors 1

Key success factors:

• Patient status at transplantation is the critical determinant—the Pesaro classification uses three risk factors (age, hepatomegaly, liver fibrosis) to stratify patients into risk classes 1
• Control iron overload before transplant to minimize organ damage 1

Standard Medical Management (When HSCT Not Available)

For all patients without a suitable donor or those awaiting transplant:

1. Regular blood transfusions:

   • Maintain hemoglobin levels to suppress ineffective erythropoiesis
   • This is life-long therapy enabling survival into the 4th-5th decade 1

2. Iron chelation therapy (mandatory with transfusions):

   • Use oral chelators: deferiprone or deferasirox 2
   • Monitor and manage iron overload aggressively—cardiac disease from iron toxicity remains the leading cause of death 3
   • Quantitative liver iron measurements guide chelation intensity

3. Management of complications:

   • Screen for endocrinopathies (growth retardation, hypogonadism, diabetes, thyroid/parathyroid dysfunction) starting before age 10 4
   • Monitor cardiac function regularly—dilated cardiomyopathy from iron deposition is preventable with proper chelation 3
   • Folic acid supplementation
   • Splenectomy only when hypersplenism causes excessive transfusion requirements 2, 3

Critical Pitfalls to Avoid

Do not delay HSCT in suitable candidates: Every year of delay increases iron accumulation and worsens transplant outcomes. The age threshold of 14 years represents a significant survival difference 1.

Do not undertransfuse: Inadequate transfusion leads to bone marrow expansion, skeletal deformities, extramedullary hematopoiesis, and increased iron absorption 3.

Do not neglect iron chelation: Even with optimal transfusion, iron overload will develop. Cardiac complications remain the primary cause of death and are entirely preventable with adherence to chelation 3.

Emerging Therapies

Gene therapy has shown initial success with the first curative case reported, though this remains in Phase 1 trials and is limited to specialized centers in industrialized countries 1. New approaches targeting ineffective erythropoiesis (activin receptor II ligands, JAK2 inhibitors) and hemoglobin chain imbalance are under investigation 5.

Global Context

While HSCT offers cure rates approaching 97% in optimal settings 2, access to matched donors, transplant centers, and optimal medical therapy remains limited outside industrialized nations. In resource-limited settings where over 3000 patients have been transplanted globally 1, standard transfusion-chelation therapy remains the primary treatment modality, with survival now extending 40-50 years when properly managed 1.